|
EP2752488B1
(en)
|
2002-11-18 |
2020-02-12 |
Roche Innovation Center Copenhagen A/S |
Antisense design
|
|
HRP20171969T1
(hr)
|
2008-10-15 |
2018-04-06 |
Ionis Pharmaceuticals, Inc. |
Modulacija ekspresije faktora 11
|
|
US9394333B2
(en)
|
2008-12-02 |
2016-07-19 |
Wave Life Sciences Japan |
Method for the synthesis of phosphorus atom modified nucleic acids
|
|
MX342945B
(es)
|
2009-07-06 |
2016-10-18 |
Ontorii Inc * |
Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
|
|
DK2620428T3
(da)
|
2010-09-24 |
2019-07-01 |
Wave Life Sciences Ltd |
Asymmetrisk hjælpegruppe
|
|
WO2012068405A2
(en)
|
2010-11-17 |
2012-05-24 |
Isis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
|
US9605019B2
(en)
|
2011-07-19 |
2017-03-28 |
Wave Life Sciences Ltd. |
Methods for the synthesis of functionalized nucleic acids
|
|
US9580708B2
(en)
|
2011-09-14 |
2017-02-28 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotides compounds
|
|
SG11201407483YA
(en)
|
2012-05-16 |
2014-12-30 |
Rana Therapeutics Inc |
Compositions and methods for modulating smn gene family expression
|
|
BR112014028634A2
(pt)
|
2012-05-16 |
2017-06-27 |
Rana Therapeutics Inc |
composições e métodos para modulação da expressão de utrn
|
|
CA2873769A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics Inc. |
Compositions and methods for modulating hemoglobin gene family expression
|
|
BR112014028644A2
(pt)
|
2012-05-16 |
2017-08-15 |
Rana Therapeutics Inc |
Composições e métodos para modulação da expressão de atp2a2
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
AU2013262709A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
KR20240148947A
(ko)
|
2012-07-13 |
2024-10-11 |
웨이브 라이프 사이언시스 리미티드 |
키랄 제어
|
|
SG11201500239VA
(en)
|
2012-07-13 |
2015-03-30 |
Wave Life Sciences Japan |
Asymmetric auxiliary group
|
|
EP2895200B1
(en)
|
2012-09-14 |
2019-11-06 |
Translate Bio MA, Inc. |
Multimeric oligonucleotide compounds
|
|
JP6452614B2
(ja)
*
|
2012-11-15 |
2019-01-16 |
ロシュ イノベーション センター コペンハーゲン エーエス |
オリゴヌクレオチドコンジュゲート
|
|
DK2951305T3
(en)
*
|
2013-01-30 |
2018-10-29 |
Hoffmann La Roche |
LNA oligonucleotide KULHYDRATKONJUGATER
|
|
PE20152002A1
(es)
|
2013-05-01 |
2016-01-21 |
Isis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion de ttr y vhb
|
|
JP6649248B2
(ja)
|
2013-05-01 |
2020-02-19 |
レグルス セラピューティクス インコーポレイテッド |
細胞取り込みの向上のための化合物および方法
|
|
SG11201508925WA
(en)
|
2013-05-01 |
2015-11-27 |
Regulus Therapeutics Inc |
Microrna compounds and methods for modulating mir-122
|
|
WO2015042447A1
(en)
|
2013-09-20 |
2015-03-26 |
Isis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
|
US9994846B2
(en)
|
2013-10-25 |
2018-06-12 |
Regulus Therapeutics Inc. |
MicroRNA compounds and methods for modulating miR-21 activity
|
|
WO2015108048A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
|
WO2015108047A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
|
ES2917473T3
(es)
|
2014-01-16 |
2022-07-08 |
Wave Life Sciences Ltd |
Diseño quiral
|
|
KR102287532B1
(ko)
|
2014-01-30 |
2021-08-11 |
에프. 호프만-라 로슈 아게 |
생분해성 컨쥬게이트를 갖는 폴리 올리고머 화합물
|
|
EP3119888B1
(en)
|
2014-03-19 |
2021-07-28 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating ataxin 2 expression
|
|
US10006027B2
(en)
|
2014-03-19 |
2018-06-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating Ataxin 2 expression
|
|
SI3757214T1
(sl)
|
2014-04-01 |
2022-08-31 |
Biogen Ma Inc. |
Sestave za moduliranje izražanja SOD-1
|
|
RS59182B1
(sr)
|
2014-05-01 |
2019-10-31 |
Ionis Pharmaceuticals Inc |
Kompozicije i postupci za modulaciju ekspresije faktora b komplementa
|
|
ES2844593T3
(es)
|
2014-05-01 |
2021-07-22 |
Ionis Pharmaceuticals Inc |
Composiciones y procedimientos para modular la expresión de la angiopoyetina de tipo 3
|
|
ES2812099T3
(es)
|
2014-05-01 |
2021-03-16 |
Ionis Pharmaceuticals Inc |
Composiciones y métodos para modular la expresión del receptor de la hormona del crecimiento
|
|
HUE052709T2
(hu)
|
2014-05-01 |
2021-05-28 |
Ionis Pharmaceuticals Inc |
Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására
|
|
GB201408623D0
(en)
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
|
BR112017001931A2
(pt)
|
2014-08-07 |
2017-11-28 |
Regulus Therapeutics Inc |
direcionamento de micrornas para distúrbios metabólicos
|
|
US10436802B2
(en)
|
2014-09-12 |
2019-10-08 |
Biogen Ma Inc. |
Methods for treating spinal muscular atrophy
|
|
CN106795200B
(zh)
|
2014-10-10 |
2020-06-19 |
豪夫迈·罗氏有限公司 |
Galnac亚磷酰胺、其核酸缀合物及其用途
|
|
SG11201703646SA
(en)
*
|
2014-11-10 |
2017-06-29 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Combination long acting compositions and methods for hepatitis c
|
|
EP3234131B1
(en)
|
2014-12-16 |
2020-04-22 |
Roche Innovation Center Copenhagen A/S |
Chiral toxicity screening method
|
|
US20170369872A1
(en)
*
|
2014-12-18 |
2017-12-28 |
Alnylam Pharmaceuticals, Inc. |
Reversir tm compounds
|
|
US10793855B2
(en)
|
2015-01-06 |
2020-10-06 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
|
WO2016115490A1
(en)
|
2015-01-16 |
2016-07-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of dux4
|
|
EP3256591A4
(en)
|
2015-02-13 |
2018-08-08 |
Translate Bio Ma, Inc. |
Hybrid oligonucleotides and uses thereof
|
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
CN107980062B
(zh)
|
2015-04-03 |
2022-11-25 |
马萨诸塞大学 |
用于靶向亨廷汀mRNA的寡核苷酸化合物
|
|
WO2016161388A1
(en)
|
2015-04-03 |
2016-10-06 |
University Of Massachusetts |
Fully stabilized asymmetric sirna
|
|
WO2016161429A1
(en)
|
2015-04-03 |
2016-10-06 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating tmprss6 expression
|
|
DK3277815T3
(da)
|
2015-04-03 |
2021-12-13 |
Univ Massachusetts |
Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser
|
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
EP3334499A4
(en)
|
2015-08-14 |
2019-04-17 |
University of Massachusetts |
BIOACTIVE CONJUGATES FOR THE RELEASE OF OLIGONUCLEOTIDES
|
|
DK3341479T3
(da)
|
2015-08-24 |
2020-02-24 |
Roche Innovation Ct Copenhagen As |
LNA-G-Proces
|
|
US20210052631A1
(en)
*
|
2015-09-25 |
2021-02-25 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
EP3355932B1
(en)
|
2015-10-02 |
2023-04-12 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugation process
|
|
SG10201912902TA
(en)
|
2015-10-09 |
2020-02-27 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods thereof
|
|
WO2017068087A1
(en)
|
2015-10-22 |
2017-04-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide detection method
|
|
HRP20241087T1
(hr)
*
|
2015-11-06 |
2024-11-08 |
Ionis Pharmaceuticals, Inc. |
Konjugirani protusmisleni spojevi za upotrebu u terapiji
|
|
KR20250078597A
(ko)
|
2015-11-06 |
2025-06-02 |
아이오니스 파마수티컬즈, 인코포레이티드 |
아포리포프로테인 (a) 발현 조정
|
|
IL281211B2
(en)
|
2015-11-12 |
2024-01-01 |
Hoffmann La Roche |
Oligonucleotides for inducing paternal ube3a expression
|
|
WO2017096395A1
(en)
|
2015-12-04 |
2017-06-08 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
|
WO2017117496A1
(en)
|
2015-12-31 |
2017-07-06 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing ataxin-2 expression
|
|
AU2017205462A1
(en)
|
2016-01-05 |
2018-06-07 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing LRRK2 expression
|
|
WO2017131236A1
(ja)
*
|
2016-01-29 |
2017-08-03 |
協和発酵キリン株式会社 |
核酸複合体
|
|
US10478503B2
(en)
|
2016-01-31 |
2019-11-19 |
University Of Massachusetts |
Branched oligonucleotides
|
|
MX2018009854A
(es)
|
2016-03-07 |
2018-11-09 |
Arrowhead Pharmaceuticals Inc |
Ligandos dirigidos para compuestos terapeuticos.
|
|
TWI840950B
(zh)
|
2016-03-14 |
2024-05-01 |
瑞士商赫孚孟拉羅股份公司 |
用於降低pd-l1表現之寡核苷酸
|
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
|
US10961271B2
(en)
|
2016-03-16 |
2021-03-30 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating KEAP1
|
|
KR102775461B1
(ko)
|
2016-04-01 |
2025-02-28 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩타이드 조성물 및 이의 용도
|
|
EP3228326A1
(en)
*
|
2016-04-05 |
2017-10-11 |
Silence Therapeutics GmbH |
Nucleic acid linked to a trivalent glycoconjugate
|
|
CN109072223B
(zh)
*
|
2016-04-08 |
2022-10-21 |
川斯勒佰尔公司 |
多聚体编码核酸及其用途
|
|
CN109153697A
(zh)
|
2016-04-14 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
三苯甲基-单-GalNAc化合物及其用途
|
|
IL299516A
(en)
|
2016-05-06 |
2023-02-01 |
Astrazeneca Ab |
Oligonucleotides conjugated to the GLP-1 receptor ligand complex and their uses
|
|
EP3472346B1
(en)
|
2016-06-17 |
2023-01-18 |
F. Hoffmann-La Roche AG |
Papd5 and papd7 inhibitors for treating a hepatitis b infection
|
|
CA3023514A1
(en)
|
2016-06-17 |
2017-12-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of gys1 expression
|
|
CN109477103A
(zh)
|
2016-06-22 |
2019-03-15 |
ProQR治疗上市公司Ⅱ |
单链rna-编辑寡核苷酸
|
|
CR20180606A
(es)
|
2016-07-01 |
2019-02-14 |
Hoffmann La Roche |
Oligonucleótidos antisentido para modular la expresión de htra1
|
|
WO2018031933A2
(en)
|
2016-08-12 |
2018-02-15 |
University Of Massachusetts |
Conjugated oligonucleotides
|
|
EP3507366B1
(en)
|
2016-09-01 |
2020-10-07 |
ProQR Therapeutics II B.V. |
Chemically modified single-stranded rna-editing oligonucleotides
|
|
CN116832169A
(zh)
|
2016-09-02 |
2023-10-03 |
箭头药业股份有限公司 |
靶向配体
|
|
KR20190065341A
(ko)
|
2016-10-06 |
2019-06-11 |
아이오니스 파마수티컬즈, 인코포레이티드 |
올리고머 화합물들의 접합 방법
|
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
|
WO2018102745A1
(en)
|
2016-12-02 |
2018-06-07 |
Cold Spring Harbor Laboratory |
Modulation of lnc05 expression
|
|
WO2018130584A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb2 expression
|
|
WO2018130585A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating relb expression
|
|
EP3568477A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rela expression
|
|
US20190338286A1
(en)
|
2017-01-13 |
2019-11-07 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rel expression
|
|
WO2018130583A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb1 expression
|
|
CN110536964A
(zh)
|
2017-03-10 |
2019-12-03 |
国立研究开发法人国立成育医疗研究中心 |
反义寡核苷酸和糖原贮积病Ia型预防或治疗用组合物
|
|
US11512312B2
(en)
|
2017-03-10 |
2022-11-29 |
The Board Of Regents Of The University Of Texas System |
Treatment of Fuchs' endothelial corneal dystrophy
|
|
MA52546A
(fr)
|
2017-04-11 |
2020-02-19 |
Arbutus Biopharma Corp |
Compositions ciblées
|
|
WO2018215049A1
(en)
*
|
2017-05-23 |
2018-11-29 |
F. Hoffmann-La Roche Ag |
Process for galnac oligonucleotide conjugates
|
|
JP6952366B2
(ja)
|
2017-05-26 |
2021-10-20 |
国立研究開発法人国立循環器病研究センター |
Ｐｃｓｋ９を標的としたアンチセンス核酸
|
|
US20190055564A1
(en)
|
2017-06-01 |
2019-02-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for modulating htra1 expression
|
|
CN120330183A
(zh)
*
|
2017-06-02 |
2025-07-18 |
波涛生命科学有限公司 |
寡核苷酸组合物及其使用方法
|
|
WO2018226788A1
(en)
*
|
2017-06-07 |
2018-12-13 |
University Of Massachusetts |
Anti-adam33 oligonucleotides and related methods
|
|
CN110799647A
(zh)
|
2017-06-23 |
2020-02-14 |
马萨诸塞大学 |
双尾自递送sirna及相关的方法
|
|
ES2984285T3
(es)
|
2017-08-10 |
2024-10-29 |
Abionyx Pharma Sa |
Cargómeros
|
|
WO2019030313A2
(en)
|
2017-08-11 |
2019-02-14 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
|
|
JP2020531450A
(ja)
|
2017-08-17 |
2020-11-05 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
調整性ｒｅｖｅｒｓｉｒ（商標）化合物
|
|
EP3668984A4
(en)
|
2017-08-18 |
2021-09-08 |
Ionis Pharmaceuticals, Inc. |
MODULATION OF THE NOTCH SIGNALING PATH FOR THE TREATMENT OF RESPIRATORY DISORDERS
|
|
WO2019038228A1
(en)
|
2017-08-22 |
2019-02-28 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
|
|
WO2019051173A1
(en)
|
2017-09-08 |
2019-03-14 |
Ionis Pharmaceuticals, Inc. |
MODULATORS OF SMAD7 EXPRESSION
|
|
WO2019075357A1
(en)
*
|
2017-10-12 |
2019-04-18 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
|
|
EP3694995A1
(en)
|
2017-10-13 |
2020-08-19 |
Roche Innovation Center Copenhagen A/S |
Methods for identifying improved stereodefined phosphorothioate oligonucleotide variants of antisense oligonucleotides utilising sub-libraries of partially stereodefined oligonucleotides
|
|
TW202424191A
(zh)
|
2017-10-16 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子
|
|
CN111386105B
(zh)
|
2017-11-06 |
2023-09-15 |
日东电工株式会社 |
用于递送生物活性分子的膜融合化合物
|
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
|
JP7273417B2
(ja)
|
2017-12-01 |
2023-05-15 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
|
|
WO2019105418A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
|
|
KR20250107294A
(ko)
|
2017-12-01 |
2025-07-11 |
쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 |
핵산, 이를 포함하는 조성물과 컨쥬게이트, 및 그의 제조 방법과 용도
|
|
WO2019105419A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
US11414661B2
(en)
|
2017-12-01 |
2022-08-16 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
|
|
CN118638787A
(zh)
|
2017-12-06 |
2024-09-13 |
艾维迪提生物科学公司 |
治疗肌萎缩和强直性肌营养不良的组合物和方法
|
|
CN111344408A
(zh)
|
2017-12-11 |
2020-06-26 |
哥本哈根罗氏创新中心 |
用于调控fndc3b表达的寡核苷酸
|
|
WO2019115417A2
(en)
|
2017-12-12 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating rb1 expression
|
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
|
CN118980816A
(zh)
|
2017-12-21 |
2024-11-19 |
豪夫迈·罗氏有限公司 |
Htra1 rna拮抗剂的伴随诊断
|
|
KR20200104347A
(ko)
|
2017-12-22 |
2020-09-03 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
포스포로디티오에이트 인터뉴클레오시드 연결을 포함하는 갭머 올리고뉴클레오티드
|
|
US20200339982A1
(en)
|
2017-12-22 |
2020-10-29 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
|
KR20200104302A
(ko)
|
2017-12-22 |
2020-09-03 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
신규 티오포스포르아미다이트
|
|
DK3732185T3
(da)
*
|
2017-12-29 |
2025-03-31 |
Suzhou Ribo Life Science Co Ltd |
Konjugater og fremstilling og anvendelse heraf
|
|
WO2019137883A1
(en)
|
2018-01-10 |
2019-07-18 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating pias4 expression
|
|
MX2020007433A
(es)
|
2018-01-12 |
2020-09-14 |
Bristol Myers Squibb Co |
Oligonucleotidos antisentido que actuan sobre alfa-sinucleina, y usos de estos.
|
|
JP2021510295A
(ja)
|
2018-01-12 |
2021-04-22 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Ｇｓｋ３ｂ発現を調節するためのオリゴヌクレオチド
|
|
EA202091693A1
(ru)
|
2018-01-12 |
2021-04-14 |
Бристол-Маерс Сквибб Компани |
Антисмысловые олигонуклеотиды, целенаправленно воздействующие на альфа-синуклеин, и их применения
|
|
KR20200109338A
(ko)
|
2018-01-12 |
2020-09-22 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
알파-시누클레인 안티센스 올리고뉴클레오티드 및 이의 용도
|
|
MX2020007369A
(es)
|
2018-01-15 |
2020-10-28 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresion de dnm2.
|
|
US20210095276A1
(en)
|
2018-01-17 |
2021-04-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating erc1 expression
|
|
US20210095277A1
(en)
|
2018-01-18 |
2021-04-01 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting srebp1
|
|
WO2019145386A1
(en)
|
2018-01-26 |
2019-08-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating csnk1d expression
|
|
JP7383618B2
(ja)
*
|
2018-01-26 |
2023-11-20 |
エフ． ホフマン－ラ ロシュ アーゲー |
放射標識オリゴヌクレオチドおよびその調製のための方法
|
|
KR20200108315A
(ko)
|
2018-02-09 |
2020-09-17 |
제넨테크, 인크. |
Tmem106b의 발현을 조절하기 위한 올리고뉴클레오티드
|
|
BR112020016347A2
(pt)
|
2018-02-21 |
2021-01-12 |
Bristol-Myers Squibb Company |
Oligonucleotídeos antisense de camk2d e seus usos
|
|
TWI840345B
(zh)
|
2018-03-02 |
2024-05-01 |
美商Ionis製藥公司 |
Irf4表現之調節劑
|
|
EP3759127A4
(en)
|
2018-03-02 |
2022-03-30 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR MODULATING AMYLOID BETA PRECURSOR PROTEIN
|
|
CN111511915A
(zh)
|
2018-03-09 |
2020-08-07 |
第一三共株式会社 |
糖原病Ia型治疗药
|
|
US11661601B2
(en)
|
2018-03-22 |
2023-05-30 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating FMR1 expression
|
|
SG11202009680XA
(en)
|
2018-04-05 |
2020-10-29 |
Hoffmann La Roche |
Use of fubp1 inhibitors for treating hepatitis b virus infection
|
|
PE20201349A1
(es)
|
2018-04-11 |
2020-11-30 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresion de ezh2
|
|
US20210269851A1
(en)
|
2018-05-07 |
2021-09-02 |
Roche Innovation Center Copenhagen A/S |
Massively parallel discovery methods for oligonucleotide therapeutics
|
|
EP3790971A1
(en)
|
2018-05-08 |
2021-03-17 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
|
JP7279081B2
(ja)
|
2018-05-08 |
2023-05-22 |
レグルス セラピューティクス インコーポレイテッド |
Ｍｉｒ－１２２を調節するためのマイクロｒｎａ化合物及び方法
|
|
WO2019217708A1
(en)
|
2018-05-09 |
2019-11-14 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing atxn3 expression
|
|
SG11202010012PA
(en)
|
2018-05-09 |
2020-11-27 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing fxi expression
|
|
TWI844541B
(zh)
|
2018-05-11 |
2024-06-11 |
新加坡商波濤生命科學有限公司 |
寡核苷酸組成物及其使用方法
|
|
BR112020022620A2
(pt)
*
|
2018-05-11 |
2021-02-17 |
Alpha Anomeric Sas |
conjugados de oligonucleotídeos que compreendem nucleosídeos de açúcar 7'-5'-alfa-anomérico-bicíclicos
|
|
GB201808146D0
(en)
|
2018-05-18 |
2018-07-11 |
Proqr Therapeutics Ii Bv |
Stereospecific Linkages in RNA Editing Oligonucleotides
|
|
JP7379387B2
(ja)
|
2018-06-05 |
2023-11-14 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ａｔｘｎ２発現を制御するためのオリゴヌクレオチド
|
|
AU2019287635B2
(en)
|
2018-06-14 |
2026-02-12 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for increasing STMN2 expression
|
|
TWI833770B
(zh)
|
2018-06-27 |
2024-03-01 |
美商Ionis製藥公司 |
用於減少 lrrk2 表現之化合物及方法
|
|
WO2020007772A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting gbp-1
|
|
WO2020007700A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting spi1
|
|
WO2020007702A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting bcl2l11
|
|
PE20220013A1
(es)
|
2018-07-03 |
2022-01-11 |
Hoffmann La Roche |
Oligonucleotidos para modular la expresion de tau
|
|
WO2020007826A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mbtps1
|
|
WO2020007889A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting stat1
|
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
|
WO2020011744A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers5
|
|
WO2020011745A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers6
|
|
WO2020011869A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting tlr2
|
|
BR112021000538A2
(pt)
|
2018-07-13 |
2021-04-06 |
F. Hoffmann-La Roche Ag |
Oligonucleotídeos para modular a expressão de rtel1
|
|
WO2020018558A1
(en)
|
2018-07-17 |
2020-01-23 |
Aronora, Inc. |
Methods for safely reducing thrombopoietin
|
|
CA3106986A1
(en)
|
2018-07-25 |
2020-01-30 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing atxn2 expression
|
|
MX2020013270A
(es)
|
2018-07-31 |
2021-02-18 |
Roche Innovation Ct Copenhagen As |
Oligonucleotidos que comprenden enlace internucleosidico de fosforotritioato.
|
|
AU2019313527A1
(en)
|
2018-07-31 |
2021-02-11 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
|
AU2019316640B2
(en)
|
2018-08-10 |
2026-03-12 |
University Of Massachusetts |
Modified oligonucleotides targeting SNPs
|
|
EP3842534A4
(en)
|
2018-08-21 |
2022-07-06 |
Suzhou Ribo Life Science Co., Ltd. |
NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE WITH NUCLEIC ACID AND THEIR USE
|
|
EP3840759A4
(en)
|
2018-08-23 |
2022-06-01 |
University Of Massachusetts |
O-METHYL RICH FULLY STABILIZED OLIGONUCLEOTIDES
|
|
WO2020038976A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting usp8
|
|
WO2020038973A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting sptlc1
|
|
WO2020038971A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting vcan
|
|
JP7499754B2
(ja)
|
2018-08-23 |
2024-06-14 |
ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブ |
Ｍｉｃｒｏｒｎａ－１３４バイオマーカー
|
|
CN113728102A
(zh)
|
2018-08-28 |
2021-11-30 |
罗氏创新中心哥本哈根有限公司 |
使用剪接调节化合物进行新抗原工程化
|
|
EP3620519A1
(en)
|
2018-09-04 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
|
|
WO2020051398A1
(en)
*
|
2018-09-06 |
2020-03-12 |
Aptamir Therapeutics, Inc. |
Metabolic benefits of short mir-22 mirna antagomir therapies
|
|
WO2020063198A1
(zh)
|
2018-09-30 |
2020-04-02 |
苏州瑞博生物技术有限公司 |
一种siRNA缀合物及其制备方法和用途
|
|
EP3873920A1
(en)
|
2018-11-01 |
2021-09-08 |
F. Hoffmann-La Roche AG |
Antisense oligonucleotides targeting tia1
|
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
|
AU2019380940A1
(en)
|
2018-11-15 |
2021-06-03 |
Ionis Pharmaceuticals, Inc. |
Modulators of IRF5 expression
|
|
EP3884053A4
(en)
|
2018-11-21 |
2023-02-01 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR REDUCING PRION EXPRESSION
|
|
EP3894559A4
(en)
|
2018-12-03 |
2023-04-05 |
Triplet Therapeutics, Inc. |
METHODS OF TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS RELATED TO MLH3 ACTIVITY
|
|
EP3898977A1
(en)
|
2018-12-20 |
2021-10-27 |
Praxis Precision Medicines, Inc. |
Compositions and methods for the treatment of kcnt1 related disorders
|
|
US20220042011A1
(en)
|
2018-12-21 |
2022-02-10 |
Hoffmann-La Roche Inc. |
Antisense oligonucleotides targeting card9
|
|
JP7507495B2
(ja)
|
2018-12-28 |
2024-06-28 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
|
|
AU2020207935A1
(en)
*
|
2019-01-18 |
2021-08-26 |
University Of Massachusetts |
Dynamic pharmacokinetic-modifying anchors
|
|
WO2020152303A1
(en)
*
|
2019-01-25 |
2020-07-30 |
F. Hoffmann-La Roche Ag |
Lipid vesicle for oral drug delivery
|
|
TW202214854A
(zh)
|
2019-01-31 |
2022-04-16 |
美商Ionis製藥公司 |
Yap1表現之調節劑
|
|
BR112021016354A2
(pt)
|
2019-02-20 |
2021-10-19 |
Roche Innovation Center Copenhagen A/S |
Composto, processo para a fabricação de um composto de fórmula, uso de um composto e invenção
|
|
CN113490742A
(zh)
*
|
2019-02-20 |
2021-10-08 |
罗氏创新中心哥本哈根有限公司 |
膦酰基乙酸酯缺口聚物寡核苷酸
|
|
EP3931348B1
(en)
|
2019-02-26 |
2023-08-09 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide formulation method
|
|
MX2021010152A
(es)
|
2019-02-27 |
2021-09-14 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresion de malat1.
|
|
WO2020178258A1
(en)
*
|
2019-03-05 |
2020-09-10 |
F. Hoffmann-La Roche Ag |
Intracellular targeting of molecules
|
|
MD3947684T2
(ro)
|
2019-03-29 |
2025-10-31 |
Ionis Pharmaceuticals Inc |
Compuși și metode pentru modularea UBE3A-ATS
|
|
US20220177894A1
(en)
|
2019-04-02 |
2022-06-09 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for immunotherapy
|
|
KR20210149107A
(ko)
|
2019-04-03 |
2021-12-08 |
브리스톨-마이어스 스큅 컴퍼니 |
Angptl2 안티센스 올리고뉴클레오티드 및 그의 용도
|
|
US11286485B2
(en)
|
2019-04-04 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Oligonucleotides for modulating ATXN2 expression
|
|
JP7499267B2
(ja)
|
2019-04-04 |
2024-06-13 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ａｔｘｎ２発現を調節するためのオリゴヌクレオチド
|
|
EP3974530A4
(en)
|
2019-05-22 |
2023-07-12 |
Suzhou Ribo Life Science Co., Ltd. |
NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, METHOD OF MANUFACTURE AND USE
|
|
CA3139195A1
(en)
|
2019-05-22 |
2020-11-26 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
|
|
JP7610849B2
(ja)
|
2019-05-24 |
2025-01-09 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、薬物組成物及び複合体ならびに調製方法と使用
|
|
US11466274B2
(en)
|
2019-05-31 |
2022-10-11 |
Aligos Therapeutics, Inc. |
Modified gapmer oligonucleotides and methods of use
|
|
CN113950529A
(zh)
|
2019-06-06 |
2022-01-18 |
豪夫迈·罗氏有限公司 |
靶向atxn3的反义寡核苷酸
|
|
EP4660307A2
(en)
|
2019-07-26 |
2025-12-10 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gfap
|
|
AU2020319911A1
(en)
*
|
2019-07-30 |
2022-02-24 |
Mpeg La, L.L.C. |
Subcutaneous delivery of multimeric oligonucleotides with enhanced bioactivity
|
|
KR20220047989A
(ko)
|
2019-08-09 |
2022-04-19 |
유니버시티 오브 매사추세츠 |
Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드
|
|
KR20220061972A
(ko)
|
2019-09-10 |
2022-05-13 |
다이이찌 산쿄 가부시키가이샤 |
간장 송달용 GalNAc-올리고뉴클레오티드 콘주게이트 및 제조 방법
|
|
US12365894B2
(en)
|
2019-09-16 |
2025-07-22 |
University Of Massachusetts |
Branched lipid conjugates of siRNA for specific tissue delivery
|
|
KR20220110729A
(ko)
*
|
2019-10-02 |
2022-08-09 |
서나오믹스, 인크. |
뉴클레오시드 유사체를 포함하는 올리고뉴클레오티드
|
|
JP7634542B2
(ja)
*
|
2019-12-19 |
2025-02-21 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用
|
|
CN114829601A
(zh)
|
2019-12-19 |
2022-07-29 |
豪夫迈·罗氏有限公司 |
Sbds抑制剂用于治疗乙型肝炎病毒感染的用途
|
|
CN114867856A
(zh)
|
2019-12-19 |
2022-08-05 |
豪夫迈·罗氏有限公司 |
Saraf抑制剂用于治疗乙型肝炎病毒感染的用途
|
|
JP7653997B2
(ja)
|
2019-12-19 |
2025-03-31 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｂ型肝炎ウイルス感染を処置するためのｃｏｐｓ３阻害剤の使用
|
|
JP2023506540A
(ja)
|
2019-12-19 |
2023-02-16 |
エフ． ホフマン－ラ ロシュ エージー． |
Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用
|
|
EP4706689A2
(en)
*
|
2019-12-19 |
2026-03-11 |
Entrada Therapeutics, Inc. |
Compositions for delivery of antisense compounds
|
|
US20210214727A1
(en)
|
2019-12-20 |
2021-07-15 |
Hoffmann-La Roche Inc. |
Enhanced oligonucleotides for inhibiting scn9a expression
|
|
EP4081639A1
(en)
|
2019-12-24 |
2022-11-02 |
F. Hoffmann-La Roche AG |
Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
|
|
EP4081217A1
(en)
|
2019-12-24 |
2022-11-02 |
F. Hoffmann-La Roche AG |
Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
|
|
EP4097234A1
(en)
|
2020-01-28 |
2022-12-07 |
Université de Strasbourg |
Antisense oligonucleotide targeting linc00518 for treating melanoma
|
|
WO2021158810A1
(en)
|
2020-02-05 |
2021-08-12 |
Bristol-Myers Squibb Company |
Oligonucleotides for splice modulation of camk2d
|
|
CN120505310A
(zh)
|
2020-02-28 |
2025-08-19 |
Ionis制药公司 |
用于调节smn2的化合物和方法
|
|
CN115176010A
(zh)
|
2020-02-28 |
2022-10-11 |
豪夫迈·罗氏有限公司 |
用于调节cd73外显子7剪接的寡核苷酸
|
|
GB2613225B
(en)
|
2020-03-04 |
2024-01-03 |
Verve Therapeutics Inc |
Compositions and methods for targeted RNA delivery
|
|
AU2021237465A1
(en)
|
2020-03-19 |
2022-10-13 |
Avidity Biosciences, Inc. |
Compositions and methods of treating Facioscapulohumeral muscular dystrophy
|
|
JP2023522957A
(ja)
*
|
2020-04-21 |
2023-06-01 |
フラッグシップ パイオニアリング， インコーポレイテッド |
二機能性分子およびその使用方法
|
|
IL297435A
(en)
|
2020-05-01 |
2022-12-01 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating atxn1
|
|
WO2021231211A1
(en)
|
2020-05-11 |
2021-11-18 |
Genentech, Inc. |
Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
|
|
WO2021231204A1
(en)
|
2020-05-11 |
2021-11-18 |
Genentech, Inc. |
Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
|
|
CN115605592A
(zh)
|
2020-05-11 |
2023-01-13 |
基因泰克公司（Us） |
用于治疗神经系统疾病的补体组分c1r抑制剂以及相关的组合物、系统和使用它们的方法
|
|
EP4150083A1
(en)
|
2020-05-13 |
2023-03-22 |
F. Hoffmann-La Roche AG |
Oligonucleotide agonists targeting progranulin
|
|
WO2021231680A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
|
EP4150078A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
|
EP4150090A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
|
EP4150077A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
|
WO2021231675A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
|
WO2021231673A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
|
US20230193269A1
(en)
|
2020-05-22 |
2023-06-22 |
Boehringer Ingelheim International Gmbh |
Oligonucleotides for splice modulation of card9
|
|
US12534724B2
(en)
|
2020-05-26 |
2026-01-27 |
University Of Massachusetts |
Synthetic oligonucleotides having regions of block and cluster modifications
|
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
|
US20230212572A1
(en)
|
2020-06-09 |
2023-07-06 |
Roche Innovation Center Copenhagen A/S |
Guanosine Analogues for Use in Therapeutics Polynucleotides
|
|
AR122731A1
(es)
|
2020-06-26 |
2022-10-05 |
Hoffmann La Roche |
Oligonucleótidos mejorados para modular la expresión de fubp1
|
|
JP7799640B2
(ja)
|
2020-06-29 |
2026-01-15 |
アイオーニス ファーマシューティカルズ， インコーポレーテッド |
Ｐｌｐ１を調節するための化合物及び方法
|
|
EP4185696A1
(en)
|
2020-07-23 |
2023-05-31 |
F. Hoffmann-La Roche AG |
Oligonucleotides targeting rna binding protein sites
|
|
WO2022018155A1
(en)
|
2020-07-23 |
2022-01-27 |
F. Hoffmann-La Roche Ag |
Lna oligonucleotides for splice modulation of stmn2
|
|
US12384814B2
(en)
|
2020-07-28 |
2025-08-12 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing app expression
|
|
CN111671913B
(zh)
*
|
2020-07-30 |
2022-02-08 |
四川大学 |
一种量子点-小核酸偶联物及其用途
|
|
PE20231567A1
(es)
|
2020-08-07 |
2023-10-04 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para modular el scn2a
|
|
JP2023538630A
(ja)
|
2020-08-21 |
2023-09-08 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｂ型肝炎ウイルス感染症を処置するためのａ１ｃｆ阻害剤の使用
|
|
JP2023545406A
(ja)
*
|
2020-10-02 |
2023-10-30 |
サーナオミクス インコーポレイテッド |
ウイルス性疾患を治療するためのヌクレオシド含有ｓｉＲＮＡ
|
|
MX2023005736A
(es)
|
2020-11-18 |
2023-05-25 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para modular la expresion de angiotensinogeno.
|
|
WO2022117745A1
(en)
|
2020-12-03 |
2022-06-09 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting atxn3
|
|
AR124227A1
(es)
|
2020-12-03 |
2023-03-01 |
Hoffmann La Roche |
Oligonucleótidos antisentido que actúan sobre atxn3
|
|
WO2022129320A1
(en)
|
2020-12-18 |
2022-06-23 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for targeting progranulin
|
|
CA3205040A1
(en)
|
2020-12-18 |
2022-06-23 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating factor xii
|
|
WO2022136140A1
(en)
|
2020-12-22 |
2022-06-30 |
F. Hoffmann-La Roche Ag |
Oligonucleotides targeting xbp1
|
|
CN114716518A
(zh)
*
|
2021-01-06 |
2022-07-08 |
圣诺制药公司 |
一种能够抑制pcsk9表达的分子构造及药物组合物
|
|
US20240083990A1
(en)
|
2021-01-26 |
2024-03-14 |
Universite Brest Bretagne Occidentale |
Novel stim1 splicing variants and uses thereof
|
|
TW202246500A
(zh)
|
2021-02-02 |
2022-12-01 |
瑞士商赫孚孟拉羅股份公司 |
用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸
|
|
PE20240696A1
(es)
|
2021-03-08 |
2024-04-10 |
Servier Lab |
Oligonucleotidos antisentido para inhibir la expresion de la alfa-sinucleina
|
|
WO2022232650A1
(en)
*
|
2021-04-30 |
2022-11-03 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing agt expression
|
|
US20240263177A1
(en)
|
2021-05-20 |
2024-08-08 |
Korro Bio, Inc. |
Methods and Compositions for Adar-Mediated Editing
|
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
|
EP4352222A1
(en)
|
2021-06-08 |
2024-04-17 |
F. Hoffmann-La Roche AG |
Oligonucleotide progranulin agonists
|
|
US12378267B2
(en)
|
2021-06-17 |
2025-08-05 |
Entrada Therapeutics, Inc. |
Synthesis of FMOC-protected morpholino monomers and oligomers
|
|
KR20240023602A
(ko)
|
2021-06-18 |
2024-02-22 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Ifnar1 발현을 감소시키기 위한 화합물 및 방법
|
|
IL309334A
(en)
|
2021-06-23 |
2024-02-01 |
Univ Massachusetts |
Anti-FLT1 optimized oligonucleotide compounds for the treatment of preeclampsia and other angiogenic disorders
|
|
US20250034564A1
(en)
|
2021-06-29 |
2025-01-30 |
Korro Bio, Inc. |
Methods and Compositions for ADAR-Mediated Editing
|
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
|
JP2024530647A
(ja)
|
2021-08-03 |
2024-08-23 |
ヴァーヴ・セラピューティクス，インコーポレーテッド |
標的ｒｎａ送達のための組成物および方法
|
|
WO2023034561A2
(en)
*
|
2021-09-02 |
2023-03-09 |
Vanderbilt University |
Lipophilic oligonucleotide conjugates
|
|
CN118265544A
(zh)
|
2021-09-16 |
2024-06-28 |
艾维迪提生物科学公司 |
治疗面肩肱型肌营养不良的组合物和方法
|
|
WO2023069603A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
|
CN118318042A
(zh)
|
2021-11-03 |
2024-07-09 |
豪夫迈·罗氏有限公司 |
用于调节载脂蛋白e4表达的寡核苷酸
|
|
IL312635A
(en)
|
2021-11-11 |
2024-07-01 |
Hoffmann La Roche |
Pharmaceutical combinations for treatment of hbv
|
|
WO2023102188A1
(en)
*
|
2021-12-03 |
2023-06-08 |
Quralis Corporation |
Gapmer antisense oligonucleotides with modified backbone chemistries
|
|
JP2025501457A
(ja)
|
2021-12-07 |
2025-01-22 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ａｃｔｌ６ｂを標的とするアンチセンスオリゴヌクレオチド
|
|
WO2023111210A1
(en)
|
2021-12-17 |
2023-06-22 |
F. Hoffmann-La Roche Ag |
Combination of oligonucleotides for modulating rtel1 and fubp1
|
|
EP4448763A1
(en)
|
2021-12-17 |
2024-10-23 |
F. Hoffmann-La Roche AG |
Oligonucleotide gba agonists
|
|
EP4453206A1
(en)
|
2021-12-20 |
2024-10-30 |
F. Hoffmann-La Roche AG |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
|
CN118613268A
(zh)
|
2022-01-20 |
2024-09-06 |
基因泰克公司 |
用于调节tmem106b表达的反义寡核苷酸
|
|
AR128558A1
(es)
|
2022-02-21 |
2024-05-22 |
Hoffmann La Roche |
Oligonucleótido antisentido
|
|
JPWO2023176862A1
(enExample)
|
2022-03-16 |
2023-09-21 |
|
|
|
WO2023176863A1
(ja)
|
2022-03-16 |
2023-09-21 |
第一三共株式会社 |
ＲＮＡｉ活性を有する化学修飾オリゴヌクレオチド
|
|
CN119173632A
(zh)
|
2022-05-10 |
2024-12-20 |
豪夫迈·罗氏有限公司 |
靶向cfp-elk1基因间区域的反义寡核苷酸
|
|
KR20250011958A
(ko)
|
2022-05-18 |
2025-01-22 |
에프. 호프만-라 로슈 아게 |
Rna 결합 단백질 부위를 표적으로 하는 개선된 올리고뉴클레오티드
|
|
EP4282964A1
(en)
*
|
2022-05-23 |
2023-11-29 |
Universitat de Valéncia |
Oligonucleotides conjugated to oleic acid and uses thereof
|
|
WO2023242324A1
(en)
|
2022-06-17 |
2023-12-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for targeting progranulin
|
|
EP4332221A1
(en)
|
2022-08-29 |
2024-03-06 |
Roche Innovation Center Copenhagen A/S |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
|
TW202421206A
(zh)
|
2022-09-06 |
2024-06-01 |
瑞士商赫孚孟拉羅股份公司 |
用於投予至眼睛之雙股ｒｎａ分子
|
|
US12152052B2
(en)
|
2022-09-23 |
2024-11-26 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing MECP2 expression
|
|
KR20250116673A
(ko)
*
|
2022-11-21 |
2025-08-01 |
펩젠 인크. |
세포-침투 펩티드, 그의 접합체 및 그의 사용 방법
|
|
WO2024126654A1
(en)
|
2022-12-14 |
2024-06-20 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting actl6b
|
|
WO2024153586A1
(en)
|
2023-01-16 |
2024-07-25 |
Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement |
Antisense molecules and their uses for the treatment of coronavirus infection, in particular the treatment of covid-19 related to sars-cov-2 infection
|
|
WO2024155957A1
(en)
|
2023-01-19 |
2024-07-25 |
Altos Labs, Inc. |
Use of regeneration factors in organ transplantation
|
|
WO2024196893A1
(en)
*
|
2023-03-17 |
2024-09-26 |
Camford Labs Inc. |
Chemically modified nucleotides
|
|
EP4689116A1
(en)
*
|
2023-03-30 |
2026-02-11 |
Ractigen Therapeutics |
Vehicles for delivering oligonucleotides and methods of use thereof
|
|
EP4705457A2
(en)
|
2023-05-04 |
2026-03-11 |
F. Hoffmann-La Roche AG |
Oligonucleotides capable of upregulating glucocerebrosidase expression
|
|
TW202508607A
(zh)
*
|
2023-05-19 |
2025-03-01 |
大陸商北京炫景瑞醫藥科技有限公司 |
雙股寡核苷酸及其共軛物和用途
|
|
AU2024301956A1
(en)
|
2023-06-16 |
2025-12-18 |
F. Hoffmann-La Roche Ag |
Double stranded oligonucleotide for modulating jak1 expression
|
|
AU2024323589A1
(en)
|
2023-08-16 |
2026-03-05 |
Les Laboratoires Servier |
Oligonucleotides for modulating kcnt1 expression
|
|
WO2026006436A1
(en)
|
2024-06-25 |
2026-01-02 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of tar dna binding protein 43 kda (tdp43)
|
|
WO2026024954A2
(en)
|
2024-07-24 |
2026-01-29 |
Altos Labs, Inc. |
Use of regeneration factors in organ transplantation
|
|
EP4711455A1
(en)
|
2024-09-11 |
2026-03-18 |
Aarhus Universitet |
Small artificial rna (smartrna) oligonucleotide for modulating protein expression
|